三博脑科医院管理集团股份有限公司的主营业务是临床医疗服务。公司的主要产品是医疗服务、药品、 供应链、其他业务。 最新一期业绩显示，2025年一季报，公司实现营业收入3.93亿元，同比16.78%；净利润3831.36万元， 同比14.56%，销售毛利率26.44%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三博脑科115.80121.165.45127.26亿行业平均 50.6062.634.53211.06亿行业中值64.3068.963.4673.29亿1药明康德21.5131.354.952962.77亿2普蕊斯 33.7828.922.6130.78亿3爱尔眼科34.6036.065.871282.24亿4诺禾致源34.7634.902.6768.67亿5诺思格 37.4738.282.8853.68亿6华康洁净37.8854.582.1136.47亿7凯莱英40.1442.022.32398.78亿8华厦眼科 40.8242.393.11181.69亿9康龙化成40.9631.553.97565.82亿10通策医疗41.1242.055.08210.85亿11万邦医药 45.823 ...

Group 1 - The core viewpoint of the article highlights that Sanbo Brain Science's stock closed at 63.72 yuan, down 3.69%, with a rolling PE ratio of 119.43 times and a total market capitalization of 13.125 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical services sector is 49.21 times, with a median of 65.65 times, placing Sanbo Brain Science at the 39th position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Sanbo Brain Science increased to 37,673, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Sanbo Brain Science Hospital Management Group Co., Ltd. primarily engages in clinical medical services, with its main products including medical services, pharmaceuticals, supply chain, and other businesses [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 393 million yuan, representing a year-on-year increase of 16.78%, and a net profit of 38.3136 million yuan, up 14.56%, with a gross profit margin of 26.44% [1]

Group 1 - The core viewpoint of the article highlights that Sanbo Brain Science's stock closed at 66.46 yuan, down 2.01%, with a rolling PE ratio of 124.57 times and a total market value of 13.69 billion yuan [1] - The average PE ratio for the medical services industry is 49.76 times, with a median of 64.18 times, placing Sanbo Brain Science at the 39th position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Sanbo Brain Science increased to 37,673, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Sanbo Brain Science Hospital Management Group Co., Ltd. primarily engages in clinical medical services, with main products including medical services, pharmaceuticals, supply chain, and other businesses [1] - In the latest quarterly report for Q1 2025, the company achieved an operating income of 393 million yuan, a year-on-year increase of 16.78%, and a net profit of 38.31 million yuan, up 14.56%, with a gross profit margin of 26.44% [1]

三博脑科医院管理集团股份有限公司的主营业务是临床医疗服务。公司的主要产品是医疗服务、药品、 供应链、其他业务。 最新一期业绩显示，2025年一季报，公司实现营业收入3.93亿元，同比16.78%；净利润3831.36万元， 同比14.56%，销售毛利率26.44%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13三博脑科112.80118.035.30123.96亿行业平均 48.1760.054.24197.19亿行业中值63.5468.763.1572.06亿1药明康德19.6028.564.502698.54亿2康龙化成 27.5628.723.67514.97亿3爱尔眼科32.5133.885.521204.84亿4普蕊斯34.1229.212.6331.09亿5诺禾致源 34.2235.362.7569.59亿6凯莱英36.7338.462.12364.96亿7华康洁净36.7452.942.0535.37亿8诺思格 36.9937.792.8452.98亿9通策医疗39.9340.784.86204.50亿10华厦眼科41.4240.822.97174.97亿11万邦医药 46.093 ...

Group 1 - The core viewpoint of the news is that Sanbo Brain Science has seen a significant increase in its stock price, reaching 57.59 yuan, which is a 5.50% rise, while its rolling PE ratio has dropped to 107.94, marking a new low in 306 days [1] - The total market capitalization of Sanbo Brain Science is 11.863 billion yuan, and it ranks 38th in the medical services industry based on PE ratio, which has an average of 46.98 and a median of 58.58 [1][2] - In terms of capital flow, on August 8, Sanbo Brain Science experienced a net outflow of 328.60 million yuan, with a total outflow of 249.01 million yuan over the past five days [1] Group 2 - The main business of Sanbo Brain Science is clinical medical services, with key products including medical services, pharmaceuticals, and supply chain operations [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 393 million yuan, representing a year-on-year increase of 16.78%, and a net profit of 38.31 million yuan, up 14.56%, with a gross profit margin of 26.44% [1]

Core Viewpoint - SF Holding's stock closed at 48.15 yuan, with a rolling PE ratio of 23.23 times, and a total market capitalization of 243.769 billion yuan, indicating a stable position within the logistics industry [1] Company Summary - SF Holding's main business is comprehensive express logistics services, including time-sensitive express, economy express, freight, cold chain, pharmaceutical delivery, same-city instant delivery, international express, international freight and agency, and supply chain [1] - In the first quarter of 2025, the company achieved operating revenue of 69.85 billion yuan, a year-on-year increase of 6.90%, and a net profit of 2.234 billion yuan, a year-on-year increase of 16.87%, with a sales gross margin of 13.30% [1] Industry Summary - The average PE ratio for the logistics industry is 25.36 times, with a median of 28.91 times, placing SF Holding at the 30th position in the industry ranking [2] - The company has received multiple international awards and national-level case certifications in logistics technology for 2024 and is the only Chinese representative to reach the finals of the 2025 Franz Edelman Award, the highest award in global operations and management science [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Sanbo Brain Science, indicating a significant increase in shareholder numbers and a high PE ratio compared to industry averages [1][2] - As of July 4, Sanbo Brain Science's closing price was 50.55 yuan, with a PE ratio of 94.75 times, and a total market capitalization of 10.413 billion yuan [1] - The average PE ratio for the medical services industry is 41.66 times, with a median of 43.26 times, positioning Sanbo Brain Science at the 39th rank within the industry [1][2] Group 2 - As of March 31, 2025, the number of shareholders for Sanbo Brain Science increased to 37,673, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The main business of Sanbo Brain Science includes clinical medical services, with key products being medical services, pharmaceuticals, and supply chain operations [1] - In the first quarter of 2025, the company reported revenue of 393 million yuan, a year-on-year increase of 16.78%, and a net profit of 38.3136 million yuan, reflecting a year-on-year growth of 14.56%, with a gross margin of 26.44% [1]

Group 1 - The core viewpoint of the articles highlights the performance and market position of SF Holding, indicating a decline in stock price and a comparison of its PE ratio with industry averages [1][2] - As of July 2, SF Holding's stock closed at 48.27 yuan, down 1.89%, with a rolling PE ratio of 22.97 times and a total market capitalization of 240.997 billion yuan [1] - In terms of capital flow, on July 2, SF Holding experienced a net outflow of 88.5187 million yuan, with a total outflow of 42.2472 million yuan over the past five days [1] Group 2 - SF Holding's main business is comprehensive express logistics services, including time-sensitive express, economy express, freight, cold chain, medical delivery, same-city instant delivery, international express, international freight and agency, and supply chain [1] - The company achieved a revenue of 69.850 billion yuan in the first quarter of 2025, representing a year-on-year increase of 6.90%, and a net profit of 2.234 billion yuan, up 16.87%, with a gross profit margin of 13.30% [1] - In 2024, SF Holding received multiple international awards and national-level case certifications in logistics technology, and it was the only Chinese representative to reach the global finals of the Franz Edelman Award in 2025 [1]

Core Viewpoint - SF Holding's stock closed at 49.15 yuan, down 2.27%, with a rolling PE ratio of 23.39 times and a total market value of 245.39 billion yuan [1] Company Summary - SF Holding specializes in comprehensive express logistics services, including time-sensitive express, economy express, freight, cold chain, pharmaceutical delivery, same-city instant delivery, international express, international freight and agency, and supply chain services [1] - In Q1 2025, the company achieved operating revenue of 69.85 billion yuan, a year-on-year increase of 6.90%, and a net profit of 2.23 billion yuan, up 16.87%, with a gross profit margin of 13.30% [1] Industry Summary - The average PE ratio for the logistics industry is 25.14 times, with a median of 26.82 times, placing SF Holding at 31st in the industry ranking [1][2] - The company has received multiple international awards and national-level case certifications in logistics technology and is the only Chinese representative to reach the finals of the 2025 Franz Edelman Award [1]

Group 1 - The core viewpoint of the article highlights that Sanbo Brain Science's stock closed at 44.79 yuan, down 1.10%, with a rolling PE ratio of 83.95 times and a total market value of 9.226 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical services sector is 40.82 times, with a median of 45.93 times, placing Sanbo Brain Science at the 38th position in the industry ranking [1] - On June 5, the net outflow of main funds for Sanbo Brain Science was 23.9984 million yuan, although there was an overall inflow of 7.3365 million yuan over the past five days [1] Group 2 - Sanbo Brain Science Hospital Management Group Co., Ltd. primarily engages in clinical medical services, with its main products including medical services, pharmaceuticals, supply chain, and other businesses [1] - The latest quarterly performance report for Q1 2025 shows that the company achieved an operating income of 393 million yuan, a year-on-year increase of 16.78%, and a net profit of 38.3136 million yuan, a year-on-year increase of 14.56%, with a sales gross margin of 26.44% [1]